WO2007076319A3 - Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses - Google Patents

Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses Download PDF

Info

Publication number
WO2007076319A3
WO2007076319A3 PCT/US2006/062223 US2006062223W WO2007076319A3 WO 2007076319 A3 WO2007076319 A3 WO 2007076319A3 US 2006062223 W US2006062223 W US 2006062223W WO 2007076319 A3 WO2007076319 A3 WO 2007076319A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
related disorders
treating obesity
compositions
mimetibodies
Prior art date
Application number
PCT/US2006/062223
Other languages
French (fr)
Other versions
WO2007076319A2 (en
Inventor
Karyn T O'neil
Kristen Picha
Vedrana Stojanovic-Susulic
Original Assignee
Centocor Inc
Karyn T O'neil
Kristen Picha
Vedrana Stojanovic-Susulic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc, Karyn T O'neil, Kristen Picha, Vedrana Stojanovic-Susulic filed Critical Centocor Inc
Priority to JP2008547703A priority Critical patent/JP2009526750A/en
Priority to EP06846650A priority patent/EP1968645A4/en
Priority to CA002634784A priority patent/CA2634784A1/en
Publication of WO2007076319A2 publication Critical patent/WO2007076319A2/en
Publication of WO2007076319A3 publication Critical patent/WO2007076319A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to at least one novel human GLP-1 mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or specified portion or variant, GLP-1 mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices for treating obesity related disorders.
PCT/US2006/062223 2005-12-22 2006-12-18 Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses WO2007076319A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2008547703A JP2009526750A (en) 2005-12-22 2006-12-18 GLP-1 agonists, compositions, methods and uses
EP06846650A EP1968645A4 (en) 2005-12-22 2006-12-18 Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses
CA002634784A CA2634784A1 (en) 2005-12-22 2006-12-18 Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75282605P 2005-12-22 2005-12-22
US60/752,826 2005-12-22

Publications (2)

Publication Number Publication Date
WO2007076319A2 WO2007076319A2 (en) 2007-07-05
WO2007076319A3 true WO2007076319A3 (en) 2008-10-30

Family

ID=38218787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/062223 WO2007076319A2 (en) 2005-12-22 2006-12-18 Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses

Country Status (4)

Country Link
EP (1) EP1968645A4 (en)
JP (1) JP2009526750A (en)
CA (1) CA2634784A1 (en)
WO (1) WO2007076319A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30820A1 (en) * 2006-12-21 2008-07-03 Centocor Inc USE OF LONG-TERM ACTION GLP-1 RECEPTOR AGONISTS TO IMPROVE INSULIN SENSITIVITY AND LIPID PROFILES
CN101918027A (en) * 2007-11-02 2010-12-15 森托科尔奥索生物科技公司 Semi-synthetic GLP-1 peptide-Fc fusion constructs, methods and uses
AU2009212747B2 (en) * 2008-01-31 2013-11-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
TWI829687B (en) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
US11208477B2 (en) 2019-04-01 2021-12-28 Novo Nordisk A/S Antibodies and use thereof
AU2021285138A1 (en) 2020-06-03 2023-02-02 Københavns Universitet GLP1R agonist NMDAR antagonist conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097175A2 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097175A2 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1968645A4 *

Also Published As

Publication number Publication date
JP2009526750A (en) 2009-07-23
EP1968645A2 (en) 2008-09-17
EP1968645A4 (en) 2009-11-04
WO2007076319A2 (en) 2007-07-05
CA2634784A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
WO2005097175A3 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2008011446A3 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2005081687A3 (en) Human hinge core mimetibodies, compositions, methods and uses
WO2007046834A3 (en) Glp-1 agonists, compositions, methods and uses
WO2005032460A3 (en) Human epo mimetic hinge core mimetibodies, compositions, methods and uses
WO2004002417A3 (en) Mammalian ch1 deleted mimetibodies, compositions, methods and uses
WO2003084477A3 (en) Mammalian cdr mimetibodies, compositions, methods and uses
WO2006124451A3 (en) Anti-il-13 antibodies, compositions, methods and uses
UA101301C2 (en) Isolated il-23pl9 antibody and use thereof
MX2010004179A (en) Human anti-amyloid antibodies, compositions, methods and uses.
WO2005028511A3 (en) Anti-amyloid antibodies, compositions, methods and uses
IL195898A (en) Isolated antibody which binds tnf, compositions comprising it and uses thereof in the preparation of medicaments for treating diseases
WO2009133573A3 (en) A homeopathic formulation
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2007022470A3 (en) Methods and compositions for treating neurological disease
WO2002072788A3 (en) Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses
WO2005005604A3 (en) Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2009052431A3 (en) Cd19 binding agents and uses thereof
WO2006036745A3 (en) Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses
WO2006084176A3 (en) Compounds and compositions as ppar modulators
WO2006105538A3 (en) Methods and compositions for treating il-21 related pathologies
WO2005112597A3 (en) Transgenic plants expressing intein modified proteins and associated processes for bio-pharmaceutical production
WO2007076319A3 (en) Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses
WO2003074073A3 (en) Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof
WO2006135694A3 (en) Uii-modulating compounds and their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008547703

Country of ref document: JP

Ref document number: 2634784

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006846650

Country of ref document: EP